Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study

Abstract

Background: Concern has been raised in India regarding the probable third wave of COVID-19 where children and young age group is thought to get affected the most. There is a lack of serological prevalence data in this age group. We have some interim data from our research for WHO unity protocol, which might help policymakers and the research community to answer such questions based on evidence. Hence, we conducted a study to compare the COVID -19 sero-positivity rate between children and adults Methods/Materials: This is part of an ongoing large multi-centric population-based sero-surveillance study. The study is being conducted in five selected states with a proposed total sample size of 10,000. We have data of 4,500 participants at the time of midterm analysis from four states of India. Total serum antibody against SARS-CoV-2 virus was assessed qualitatively by using a standard ELISA kit. Here we are reporting the interim data of serological prevalence among children aged between 2 to 17 years along with a comparison with ≥18-year old participants. Results: The data collection period was from 15th March 2021 to 10th June 2021. Total available data was of 4,509 participants out of which <18 years were 700 and ≥18 years was 3,809. The site-wise number of available data among the 2-17 year age group were 92, 189, 165, 146 and 108 for the site of Delhi urban resettlement colony, Delhi rural (Villages in Faridabad district under Delhi NCR), Bhubaneswar rural, Gorakhpur rural and Agartala rural area respectively. The seroprevalence was 55.7% in the <18 years age group and 63.5% in the ≥ 18 year age group. There was no statistically significant difference in prevalence between adult and children. Conclusion: SARS-CoV-2 sero-positivity rate among children was high and were comparable to the adult population. Hence, it is unlikely that any future third wave by prevailing COVID-19 variant would disproportionately affect children two years or older.

Study of Seroprevalence of SARS CoV2 antibodies in children in a diagnostic centre of Central India-a retrospective study

“…In the study by Brittany K. Smith et al in Missouri USA, the authors reported an overall positivity rate of 1.71% in paediatric population with a significantly lower seropositivity rate in children below 5 years of age. 13 Danilo B et al conducted a study in the household contacts 16 Our study correlated with this study. He S. Yang et al studied the association of age with SARSCoV2 antibody response and found that adolescents showed higher median antibody levels.…”

Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June–July 2021: A population-based cross-sectional study

“…recent study conducted in March-June 2021 among children from 5 sites in India [16]. Among the 700 individuals aged <18 years surveyed in this study, 55.7% were seropositive.…”

Resurgence of SARS-CoV-2 in India: Potential role of the B.1.617.2 (Delta) variant and delayed interventions

“…While we characterize effects of NPI on reported cases this only captures a small fraction of infections. The more recent serosurveys that are emerging indicate 55% seropositivity in age-groups 0-17 and 63% in adults in urban areas (63). Second, the lack of disaggregation of cases and deaths attributed to COVID-19 in the data available at the time of this study prohibits any investigation into differences within age-sex strata and identify vulnerable, underserved subgroups.…”